Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension.
An estimated prevalence of pulmonary hypertension at the population level is approximately 1% to 3%. The total prevalent cases of PAH in the 7MM were found to be approximately 88K cases in 2022, which are expected to increase by 2034 at a CAGR of 0.4% during the study period (2020─2034). It is observed females are more affected by PAH than males. According to DelveInsight’s estimates in 2022, the gender-specific diag...
